Let Volatility Power Your Micro-Cap Biotechs

Source: George Mack of The Life Sciences Report  (04/27/2016)
Let Volatility Power Your Micro-Cap Biotechs
ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock—no matter how far into the depths it may have sunk—and presents his detailed growth theory on two names, plus two picks for investors to do further diligence on. read more >
Management Q&A: View from the Top

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (04/27/2016)
Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. read more >
Management Q&A: View from the Top

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (04/20/2016)
Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. read more >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer

Source: George S. Mack of The Life Sciences Report   (04/20/2016)
What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease. In this interview, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to extend the lives of thousands of men. read more >

Drug Pricing, Presidential Politics, and Three Biotechs with Promise

Source: George S. Mack of The Life Sciences Report  (04/13/2016)
Drug Pricing, Presidential Politics, and Three Biotechs with Promise
George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold. read more >

How Three Companies Have Been Resurrected from Failed Clinical Trials: George Zavoico of JonesTrading

Source: George Mack of The Life Sciences Report  (04/06/2016)
How Three Companies Have Been Resurrected from Failed Clinical Trials: George Zavoico of JonesTrading
Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story. George Zavoico of JonesTrading Institutional Services discusses the growth prospects of three biotech names that have been wrecked and left for dead, but could ultimately resurrect themselves from a misleading pile of rubble. read more >
Management Q&A: View from the Top

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans

Managment Q&A: View from the Top
Source: Staff of The Life Sciences Report  (04/05/2016)
Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans
Frank Oakes, CEO of Stellar Biotechnologies, has a passion for the potential cures the ocean may provide. His company, a world leader in the production of GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH. In this interview, Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. read more >
Expert Investing Ideas

"We are initiating coverage on DRRX with a Buy rating."

–Ram Selvaraju, Rodman & Renshaw


"Significant potential remains in Europe for SNSS' Qinprezo."

–Maxim Jacobs, Edison Investment Research


"SNSS is going after registration for vosaroxin in the European Union."

The Life Sciences Report Interview with George Zavoico


NASDAQ Biotech ARCA Pharmaceutical
Management Q&A: View from the Top

Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report  (03/30/2016)
Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. Diffusion Pharmaceuticals CEO David Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer that, if successful, could drive the company's market cap to valuations that would bring huge upside to investors. read more >
Management Q&A: View from the Top

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (03/29/2016)
Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview, Moseda CEO Dr. Lisa Crossley describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home while reducing the cost of care. read more >

VANC Pharmaceuticals Could Earn 75% Net Margin with OTC Iron Supplement

Contributed Opinion
Source: Nick Hodge, Outsider Club  (03/28/2016)
VANC Pharmaceuticals Could Earn 75% Net Margin with OTC Iron Supplement
On March 7, VANC Pharmaceuticals announced the launch of a new over-the-counter (OTC) iron supplement called Hema-Fer. As the company gears up to market Hema-Fer across Canada, it is important to understand that VANC sells two types of products: generic prescription drugs and over-the-counter products. read more >

How to Trade Sarepta Therapeutics Ahead of ADCOM: Chen Lin

Contributed Opinion
Source: Chen Lin, What Is Chen Buying? What Is Chen Selling?  (03/24/2016)
How to Trade Sarepta Therapeutics Ahead of ADCOM: Chen Lin
Sarepta Therapeutics Inc. (SRPT:NASDAQ) is scheduled to have its FDA Advisory Committee Meeting (ADCOM) to review eteplirsen as a treatment for Duchenne muscular dystrophy on April 25. In this article, newsletter writer Chen Lin lays out his investment thesis on the stock ahead of the meeting, and his hopes for eteplirsen's approval. read more >
Biotech Watchlist 2016